Part 1

Part 1

Part 1

Part 1

Part 1

Part 1

Part 2

Part 2

The number of patients who experience MRD negativity (10\^-5 sensitivity by 12 cycles of linvoseltamab (MRD conversion rate) will be determined by dividing this number of MRD negative responses by the total number of evaluable patients. MRD negativity rate (\<10\^-5) by 12 cycles of linvoseltamab

The rate of MRD-negativity among participants. Defined by rate of MRD negativity using clonoSEQ MRD® assay at sensitivities of 10\^-5 and 10\^-6. MRD negativity is defined as 0 residual clonal cells in a bone marrow biopsy sample

Part 1 An AEI is a toxicity potentially related to study treatment that may preclude dose escalation or expansion according to the Bayesian Optimal Interval (BOIN) design decision rules

Part 1 As assessed by the NCI-CTCAE grading system version 5 (for all grades)

Part 1 As assessed by the NCI-CTCAE grading system version 5 (for all grades)

Part 2

AESI include grade 2 or higher Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Phase 1

Phase 1

Phase 1

Phase 2

Phase 2

Phase 2

Phase 2

Phase 1

Phase 1

Phase 1

Phase 2

Phase 2

Phase 1

Phase 2

Phase 1

Phase 1

Phase 2

Phase 2 Transplant-eligible cohort

Phase 2 Transplant-eligible cohort

Phase 2 Transplant-ineligible cohort

Phase 2 Transplant ineligible cohort

Dose finding portion only

≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE v5.0\]

Phase 1 and Phase 2 for Japanese cohort only

Phase 1

Phase 1

Phase 1 part 2

Phase 2, for Japanese cohort only

Phase 2, cohorts 1 and 2

Phase 2, cohort 3

Phase 2, cohort 3